Abstract
Prostate-specific membrane antigen (PSMA) is a target for immunotherapy of prostate cancer. It has been shown that antibodies against PSMA inhibited the in vivo growth of LNCaP tumor. In the present study, monoclonal antibodies against four epitopes in PSMA were raised. MAb 24.4E6 (IgG1), specific for the epitope (residues 638–657) in PSMA, significantly reduced the growth rate of established LNCaP tumor in SCID mice. Mouse IgG was detected in the tumor of mice treated with 24.4E6, but not with an unrelated MAb. These results suggest that this epitope may be the main target in PSMA for antibody therapy of prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ghosh A, Heston WD . Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528–539.
Barrett AJ . Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme Nomenclature. Recommendations 1992. Supplement 4: corrections and additions (1997). Eur J Biochem 1997; 250: 1–6.
Carter RE, Feldman AR, Coyle JT . Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93: 749–753.
Luthi-Carter R et al. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998; 286: 1020–1025.
Israeli RS et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227–230.
Su SL et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995; 55: 1441–1443.
Schmittgen TD et al. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 323–329.
Liu H et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629–3634.
Chang SS et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192–3198.
Kuratsukuri K et al. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Intl J Cancer 2002; 102: 244–249.
Davis MI et al. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Pro Natl Acad Sci USA 2005; 102: 5981–5986.
Dakappagari NK et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60: 3782–3789.
Kaumaya PTP et al. ‘De novo’ engineering of peptide immunogenic and antigenic determinants as potential vaccines. In: Basava C, Anantharamaiah GM (eds). Peptides: Design, Synthesis and Biological Activity. Birkhauser: Boston, 1994, pp 133–164.
Land SJ et al. Purification and characterization of a rat hepatic acetyltransferase that can metabolize aromatic amine derivatives. Carcinogenesis 1993; 14: 1441–1449.
Bumke MA, Neri D . Affinity measurements by band shift and competition ELISA. In: Kontermann R, Dubel S (eds). Antibody Engineering. Springer-Verlag: New York, 2001, pp 385–396.
Soos G et al. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res 1997; 17: 4253–4258.
Slusher BS et al. Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 1990; 265: 21297–21301.
Bacich DJ et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001; 12: 117–123.
Horoszewicz JS, Kawinski E, Murphy GP . Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927–936.
Sokoloff RL et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150–157.
Grauer LS et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998; 58: 4787–4789.
Crawford ED et al. Hormone refractory prostate cancer. Urol 1999; 54: S1–S7.
Sanda MG et al. Molecular characterization of defective antigen presentation in human prostate cancer. J Natl Cancer Inst 1995; 87: 280–285.
Blades RA et al. Loss of class I expression in prostate cancer: implications for immunotherapy. Urol 1995; 46: 681–687.
Bander N et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233–239.
Bander NH et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars Oncol 2003; 30: 667–676.
Bander NH et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717–1721.
Henry MD et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64: 7995–8001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kinoshita, Y., Kuratsukuri, K., Newman, N. et al. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Prostate Cancer Prostatic Dis 8, 359–363 (2005). https://doi.org/10.1038/sj.pcan.4500835
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500835
Keywords
This article is cited by
-
A network biology approach to prostate cancer
Molecular Systems Biology (2007)
-
Folh1
AfCS-Nature Molecule Pages (2006)
-
Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues
World Journal of Surgery (2006)